Elopag is identified on this website as a product containing eltrombopag in a stated 20 mg strength. Eltrombopag is an oral prescription medicine belonging to a class known as thrombopoietin receptor agonists. It is used in selected patients with certain conditions associated with low platelet counts or impaired blood-cell production.
Clinical information about eltrombopag includes its pharmacological action, approved treatment settings, expected treatment response, laboratory monitoring and potential complications. These factors are important because treatment is not simply intended to increase platelet numbers. Healthcare professionals must consider the patient’s underlying condition, bleeding risk, medical history and response to therapy.
The clinical information below describes eltrombopag as an active ingredient. It should not be interpreted as confirmation of every product-specific detail or as a substitute for the official prescribing information applicable to a particular Elopag product and country.
1. Active Ingredient and Drug Classification
The active ingredient identified for Elopag is eltrombopag.
Eltrombopag is classified as a thrombopoietin receptor agonist. It acts on the thrombopoietin receptor, also known as c-Mpl, which plays an important role in the development and production of platelets.
Platelets are small blood components produced in the bone marrow. They help form blood clots and reduce bleeding when blood vessels are injured. When platelet levels become too low, a person may have an increased risk of bruising or bleeding.
Eltrombopag stimulates the thrombopoietin receptor and supports the production of platelets. Its effect is different from that of medicines that directly replace platelets or treat bleeding episodes.
2. Mechanism of Action
Eltrombopag works by interacting with the thrombopoietin receptor on blood-cell precursor cells in the bone marrow.
The thrombopoietin receptor is involved in the development of megakaryocytes, which are large bone marrow cells responsible for producing platelets.
The general process can be understood in the following stages:
- Eltrombopag is absorbed after oral administration.
- It reaches the bone marrow through the bloodstream.
- It interacts with the thrombopoietin receptor on relevant precursor cells.
- Receptor activation supports signaling pathways involved in megakaryocyte development.
- Increased megakaryocyte activity can support platelet production.
- Platelet counts may increase over the course of treatment.
Eltrombopag binds to a different site on the thrombopoietin receptor from the natural thrombopoietin ligand. This pharmacological action helps explain how the medicine can stimulate platelet production.
The treatment response varies between patients. The underlying disease, previous treatments, liver function, other medicines and individual biological factors can influence the response.
3. Clinical Uses of Eltrombopag
Eltrombopag has several clinical applications, but its approved uses depend on the product label and country.
Chronic Immune Thrombocytopenia
Immune thrombocytopenia, commonly called ITP, is an immune-mediated condition in which the body’s immune system contributes to the destruction of platelets and may also affect platelet production.
People with ITP may experience:
- Easy bruising.
- Small red or purple spots on the skin called petechiae.
- Nosebleeds.
- Bleeding gums.
- Heavy menstrual bleeding.
- Prolonged bleeding after minor injuries.
Eltrombopag may be prescribed for selected adults and children with persistent or chronic ITP who have not responded adequately to certain previous treatments. Depending on the applicable label, these treatments may include corticosteroids, immunoglobulins or splenectomy.
The aim is generally to achieve a platelet count sufficient to reduce clinically important bleeding risk. The goal is not necessarily to return the platelet count to the normal range.
Severe Aplastic Anemia
Severe aplastic anemia is a serious bone marrow disorder in which the bone marrow does not produce enough blood cells.
The condition can affect:
- Red blood cells, which carry oxygen.
- White blood cells, which help fight infections.
- Platelets, which support blood clotting.
Eltrombopag may be used in specific severe aplastic anemia treatment settings. Depending on the applicable authorization, it may be used in patients with refractory disease or alongside standard immunosuppressive therapy in selected newly diagnosed patients.
Treatment requires specialist assessment and monitoring because aplastic anemia can involve multiple abnormalities in blood-cell production.
Chronic Hepatitis C-Associated Thrombocytopenia
Eltrombopag has also been used in selected patients with thrombocytopenia associated with chronic hepatitis C.
In certain interferon-based treatment settings described in prescribing information, increasing platelet counts may help patients initiate or maintain antiviral treatment.
This use is dependent on the applicable clinical and regulatory context. It should not be assumed that eltrombopag is routinely indicated for every patient with hepatitis C or low platelet counts.
4. Clinical Assessment Before Treatment
Before prescribing eltrombopag, a healthcare professional should evaluate the patient’s medical condition and determine whether treatment is appropriate.
The assessment may include:
Medical history: Previous blood disorders, liver disease, bleeding episodes, blood clots and other relevant health conditions should be reviewed.
Previous treatments: The healthcare professional may consider which treatments have already been tried and how the patient responded.
Blood tests: A complete blood count, including platelet count, helps assess the patient’s baseline condition.
Liver function: Liver function testing is important because eltrombopag can cause liver-related adverse effects.
Other medicines: Prescription medicines, nonprescription products, vitamins, minerals and supplements should be reviewed for potential interactions.
Pregnancy and breastfeeding considerations: Patients who are pregnant, planning pregnancy or breastfeeding should discuss the potential risks and benefits with their healthcare professional.
The assessment helps establish an appropriate treatment plan and monitoring schedule.
5. Clinical Monitoring During Treatment
Monitoring is an important part of eltrombopag therapy. The purpose is to assess treatment response, identify potential complications and guide dose adjustments when necessary.
Platelet Count Monitoring
Regular platelet-count testing helps determine whether the medicine is producing the intended response.
The healthcare professional may use platelet results to assess whether the treatment is effective, whether the dose needs adjustment and whether platelet counts have become excessively high.
A platelet count that rises too far may increase the risk of thrombotic or thromboembolic complications.
Liver Function Monitoring
Eltrombopag may cause liver-related abnormalities, including potentially serious hepatotoxicity.
Liver function tests may include measurements such as:
- Alanine aminotransferase (ALT).
- Aspartate aminotransferase (AST).
- Bilirubin.
Testing is generally required before treatment and periodically during therapy according to the applicable prescribing information.
Patients should promptly report symptoms that may indicate liver problems, such as yellowing of the skin or eyes, dark urine, unusual fatigue or pain in the upper right part of the abdomen.
Blood Count Monitoring
Depending on the underlying condition, healthcare professionals may monitor other blood-cell measurements as well as platelet counts.
For patients with aplastic anemia, monitoring may be particularly important because the disease can affect several types of blood cells.
Monitoring After Treatment Discontinuation
Platelet counts may decrease after eltrombopag is stopped. Patients may therefore require continued blood-count monitoring after discontinuation.
The monitoring period and frequency should follow the applicable prescribing information and the treating clinician’s instructions.
6. Important Pharmacological Considerations
Eltrombopag has specific absorption and interaction characteristics that can affect its administration.
Food and Calcium
Eltrombopag absorption can be reduced by food or products containing significant amounts of polyvalent cations.
These include calcium, iron, magnesium, aluminium and zinc.
Depending on the product formulation and prescribing information, patients may be instructed to take eltrombopag without food or with a meal containing a low amount of calcium.
The timing of eltrombopag should also be separated from certain mineral supplements, antacids and calcium-rich foods according to the official product instructions.
Patients should ask a pharmacist for help planning the timing of medicines and meals.
Drug Interactions
Medicines and supplements may affect eltrombopag absorption or exposure. The healthcare professional should review the complete medication list before treatment and whenever another medicine is added or discontinued.
Patients should not assume that vitamins, mineral supplements or nonprescription antacids are harmless to take at the same time as eltrombopag.
Liver Function
Because eltrombopag can affect liver function, patients with existing liver disease may require particular attention and dose considerations under the applicable prescribing information.
7. Important Clinical Safety Considerations
Eltrombopag can provide a therapeutic benefit in selected patients, but it also has important safety risks.
Hepatotoxicity
Eltrombopag can cause liver injury, which may be serious. Regular liver-function monitoring is important.
In certain chronic hepatitis C treatment settings involving interferon and ribavirin, additional concerns about hepatic decompensation are described in prescribing information.
Thrombotic and Thromboembolic Events
An excessive increase in platelet counts may increase the risk of blood clots. Portal vein thrombosis has been reported in patients with chronic liver disease receiving eltrombopag.
The medicine should therefore be adjusted according to clinical response rather than used to achieve an unnecessarily high platelet count.
Cataracts
Eye-related complications, including cataracts, have been reported in eltrombopag treatment settings. Appropriate eye assessment and follow-up may be recommended according to the patient’s circumstances and applicable prescribing information.
Bone Marrow and Blood Disorder Considerations
Patients with underlying bone marrow disorders require specialist supervision. The risks and benefits of eltrombopag may differ according to the diagnosis and treatment setting.
The applicable prescribing information should be consulted for specific warnings concerning the patient’s condition.
8. Clinical Response and Treatment Goals
The response to eltrombopag is not identical for every patient.
In ITP, treatment generally aims to maintain a platelet count that reduces the risk of clinically important bleeding. In severe aplastic anemia, treatment response may involve improvements in one or more blood-cell measurements, depending on the treatment setting.
A response in laboratory results does not necessarily mean that the underlying disease has been cured.
Healthcare professionals evaluate treatment using clinical symptoms, blood tests, treatment tolerance and the patient’s overall condition.
Patients should not independently increase the dose if their platelet count remains low. Dose changes should be made only by the prescribing clinician.
9. Elopag 20 mg: Product-Specific Clinical Considerations
Elopag is identified on this website as containing eltrombopag 20 mg. However, the stated strength alone does not establish the appropriate treatment dose for a patient.
Eltrombopag dosing can vary according to:
- The medical condition being treated.
- The patient’s age.
- Liver function.
- Previous treatment response.
- Platelet-count results.
- Other medicines being used.
- The formulation and official product information.
Different eltrombopag products and formulations may not always be interchangeable on a milligram-for-milligram basis. Patients should not substitute one product for another without professional guidance.
The actual Elopag packaging and official leaflet should be checked to confirm the product’s strength, formulation and administration instructions.
10. Clinical Information and Professional Guidance
Eltrombopag is a specialized prescription medicine that requires an individualized treatment plan. Its clinical role depends on the diagnosis, treatment history, applicable authorization and the patient’s overall health.
Patients should attend scheduled appointments, complete recommended blood tests and inform their healthcare professional about new symptoms or changes in other medicines.
Any suspected serious adverse reaction should receive prompt medical assessment. Patients should not stop or change treatment without discussing it with their healthcare professional, unless emergency medical advice directs otherwise.
Frequently Asked Questions
What is the drug class of eltrombopag?
Eltrombopag belongs to the thrombopoietin receptor agonist class of medicines. It stimulates a receptor involved in platelet production.
How does eltrombopag increase platelet counts?
Eltrombopag activates the thrombopoietin receptor on relevant bone marrow precursor cells, supporting megakaryocyte development and platelet production.
Which conditions may be treated with eltrombopag?
Depending on the applicable prescribing information, eltrombopag may be used in selected patients with chronic immune thrombocytopenia, severe aplastic anemia and chronic hepatitis C-associated thrombocytopenia in certain treatment settings.
Why are platelet counts monitored?
Platelet counts help healthcare professionals evaluate treatment response and identify excessive increases that could increase the risk of blood clots.
Does eltrombopag affect liver function?
Yes. Eltrombopag can cause liver-related abnormalities and potentially serious hepatotoxicity. Liver function should be monitored according to the applicable prescribing information.
Can food affect eltrombopag absorption?
Yes. Calcium-rich foods and products containing minerals such as iron, magnesium and aluminium can reduce absorption. Patients should follow the product-specific food and administration instructions.
Is Elopag 20 mg suitable for every patient with low platelets?
No. A low platelet count can have many causes. Eltrombopag is appropriate only for selected conditions and patients after professional assessment.
Does an increased platelet count mean the disease is cured?
No. An increase in platelet count is a treatment response, not necessarily a cure. The underlying condition may still require ongoing management and monitoring.
Medical Disclaimer
This page provides general clinical and educational information about eltrombopag. It does not replace the official prescribing information, professional medical advice or an individualized treatment plan.
The clinical uses and dosing recommendations for eltrombopag may differ between countries and products. Patients should follow the prescribing information applicable to their specific medicine and consult their healthcare professional before making treatment decisions.
References
The clinical information on this page should be checked against current authoritative prescribing and regulatory documentation, including:
- U.S. Food and Drug Administration (FDA), PROMACTA (eltrombopag) Prescribing Information.
- U.S. National Library of Medicine, DailyMed, official eltrombopag prescribing information.
- Applicable national medicines regulatory authority product information.
- Official patient information leaflet supplied with the specific eltrombopag product.
Product-specific note: The clinical information above concerns eltrombopag generally. It does not independently verify the manufacturer, regulatory authorization or complete prescribing information of Elopag 20 mg.